256 related articles for article (PubMed ID: 20603657)
1. Pharmaceutical trademarks: navigating through the FDA's pilot program.
Ferrer E
Drug News Perspect; 2010 Jun; 23(5):333-6. PubMed ID: 20603657
[TBL] [Abstract][Full Text] [Related]
2. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
3. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
4. FDA's role in administering the Hatch-Waxman Act.
Malkin BJ
Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
[No Abstract] [Full Text] [Related]
5. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
6. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
7. FDA's role in making exclusivity determinations.
Dickinson EH
Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573
[No Abstract] [Full Text] [Related]
8. FDA's regulation of prescription drug labeling: a role for implied preemption.
Kendrick LC
Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
[No Abstract] [Full Text] [Related]
9. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
10. New drugs for human use; clarification of requirements for patent holder notification--FDA. Proposed rule.
Fed Regist; 1998 Mar; 63(44):11174-7. PubMed ID: 10177511
[TBL] [Abstract][Full Text] [Related]
11. The errors of error testing: potential liability issues for medication error testing of pharmaceutical trademarks under U.S. law.
Thomas JA
Food Drug Law J; 2004; 59(2):325-37. PubMed ID: 15298014
[No Abstract] [Full Text] [Related]
12. Drug development and patent law.
Nusbaum NJ
N Y State J Med; 1992 Mar; 92(3):86-7. PubMed ID: 1557205
[No Abstract] [Full Text] [Related]
13. Biomarker qualification pilot process at the US Food and Drug Administration.
Goodsaid F; Frueh F
AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
[TBL] [Abstract][Full Text] [Related]
14. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
James JS
AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
[TBL] [Abstract][Full Text] [Related]
15. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
Dorfman HL; Quinn VM; Brophy EA
Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
[No Abstract] [Full Text] [Related]
16. Has the FDA Amendments Act of 2007 impaired drug development?
Franson TR
Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
[TBL] [Abstract][Full Text] [Related]
17. Current FDA directives for promoting public health.
Hayes AH
Am J Hosp Pharm; 1982 Mar; 39(3):427-31. PubMed ID: 7072727
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
19. FDA policy on unapproved drug products: past, present, and future.
Chhabra R; Kremzner ME; Kiliany BJ
Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
[TBL] [Abstract][Full Text] [Related]
20. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
